Review on usage of vancomycin in livestock and humans: Maintaining its efficacy, prevention of resistance and alternative therapy

Veterinary Sciences

Volumn 4, Issue 1, 2017, Pages

  Wijesekara, Panditharathnalage Nishantha Kumara ^a   Kumbukgolla, Wikum Widuranga ^b   Jayaweera, Jayaweera Arachchige Asela Sampath ^b   Rawat, Diwan ^c  

^a University Grants Commission   (Sri Lanka)

^b RAJARATA UNIVERSITY OF SRI LANKA   (Sri Lanka)

^c UNIVERSITY OF DELHI   (India)

Author keywords

Alternatives; Broad view; Rational use; Vancomycin; Veterinary use at a glance

Indexed keywords

EID: 85029391762     PISSN: None     EISSN: 23067381     Source Type: Journal    
DOI: 10.3390/vetsci4010006     Document Type: Review

References (78)

1. Moellering, R.C., Jr. Vancomycin: A 50-year reassessment. Clin. Infect. Dis. 2006, 42, S3-S4
2. Mark, G.P. Saunders Handbook of Veterinary Drugs Small and Large Animal, 3rd ed.; Saunders: Philadelphia, PA, USA, 2011
3. Bassetti, M.; Temperoni, C.; Astilean, A. Review: New antibiotics for bad bugs: Where are we? Ann. Clin. Microbiol. Antimicrob. 2013, 12, 1-15
4. Bennett, P.N.; Brown, M.J. Vancomycin, Clinical Pharmacology, 9th ed.; Churchill Livingstone: London, UK, 2000
5. John, F.P.; Baggot, J.D.; Walker, R.D. Glycopeptides: Vancomycin, Teicoplanin, and Avoparcin, Antimicrobial Therapy in Veterinary Medicine, 3rd ed.; Blackwell Publishing Professional: Ames, IA, USA, 2000
6. Dana, G.A.; Dowling, M.; Smith, D.A. Vancomycin. In Handbook of Veterinary Drugs, 3rd ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2005
7. Cetinkaya, Y.; Falk, P.; Mayhall, C.G. Vancomycin-Resistant Enterococci. Clin. Microbiol. Rev. 2000, 13, 686-707
8. Cynthia, M.K. Vancomycin. In Merck Veterinary Manual, 10th ed.; Merck Sharp & Dohme Corp.: Kenilworth, NJ, USA, 2010; Available online: http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/191279. htm (accessed on 3 August 2016)
9. Gungor, S.; Charro, M.B.D.; Perez, B.R.; Schubert, W.; Isom, P.; Moslemy, P.; Patane, M.A.; Guy, R.H. Trans-scleral iontophoretic delivery of low molecular weight therapeutics. J. Control. Release 2010, 147, 225-231
10. Hubbard, B.K.;Walsh, C.T. Vancomycin Assembly: Nature'sWay. Angew. Chem. 2003, 42, 730-765
11. Reynolds, P.E. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 1989, 8, 943-950
12. Nitanai, Y.; Kikuchi, T.; Kakoi, K.; Hanamaki, S.; Fujisawa, I.; Aoki, K. Crystal structures of the complexes between vancomycin and cell-wall precursor analogs. J. Mol. Biol. 2009, 385, 1422-1432
13. Zaghlol, H.A.; Brown, S.A. Single-and multiple-dose pharmacokinetics of intravenously administered vancomycin in dogs. Am. J. Vet. Res. 1988, 49, 1637-1640
14. LaPlante, K.L.; Rybak, M.J. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 2004, 48, 4665-4672
15. Levison, M.E.; Levison, J.H. Pharmacokinetics and Pharmacodynamics of Antibacterial Agents. Infect. Dis. Clin. N. Am. 2009, 23, 791-815
16. Cantu, T.G.; Dick, J.D.; Elliott, D.E.; Humphrey, R.L.; Kornhauser, D.M. Protein binding of vancomycin in a patient with immunoglobulin A myeloma. Antimicrob. Agents Chemother. 1990, 34, 1459-1461
17. Micek, S.T. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 2007, 45, S184-S190
18. Koteva, K.; Hong, H.L.; Wang, X.D.; Nazi, I.; Hughes, D.; Naldrett, M.J.; Buttner, M.J.; Wright, G.D. A vancomycin photoprobe identifies the histidine kinase VanSsc as a vancomycin receptor. Nat. Chem. Biol. 2010, 6, 327-329
19. Albanese, J.; Leone, M.; Bruguerolle, B.; Ayem, M.L.; Lacarelle, B.; Martin, C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob. Agents Chemother. 2000, 44, 1356-1358
20. Nau, R.; Sörgel, F.; Eiffert, H. Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections. Clin. Microbiol. Rev. 2010, 23, 858-883
21. Matzneller, P.; Burian, A.; Zeitlinger, M.; Sauermann, R. Understanding the Activity of Antibiotics in Cerebrospinal Fluid in vitro. Pharmacology 2016, 97, 233-244
22. Forouzesh, A.; Moise, P.A.; Sakoulas, G. Vancomycin ototoxicity: A reevaluation in an era of increasing doses. Antimicrob. Agents Chemother. 2009, 53, 2483-2486
23. Chavers, L.S.; Moser, S.A.; Benjamin, W.H.; Banks, S.E.; Steinhauer, J.R.; Smith, A.M.; Johnson, C.N.; Funkhouser, E.; Chavers, L.P.; Stamm, A.M.; et al. Vancomycin-resistant enterococci: 15 years and counting. J. Hosp. Infect. 2003, 53, 159-171
24. Anuradha, G.; Scot, D.E.; Ludek, Z. Dogs Leaving the ICU Carry a Very Large Multi-Drug Resistant Enterococcal Population with Capacity for Biofilm Formation and Horizontal Gene Transfer. PLoS ONE 2011, 6 Available online: http://journals.plos.org/plosone/article/file (accessed on 1 January 2017)
25. Leekha, S.; Terrell, C.L.; Edson, R.S. General Principles of Antimicrobial Therapy. Mayo. Clin. Proc. 2011, 86, 156-167
26. Cheong, J.Y.; Bakry, M.M.; Lau, C.L.; Rahman, R.A. The relationship between trough concentration of vancomycin and effect on methicillin-resistant Staphylococcus aureus in critically ill patients. S. Afr. Med. J. 2012, 102, 616-619
27. Wu, C.; Shen, L.; Hsu, L.; Ko, W.;Wu, F.L. Pharmacokinetics of vancomycin in adults receiving extracorporeal membrane oxygenation. J. Formos. Med. Assoc. 2016, 115, 560-570
28. Cisek, A.A.; Rzewuska, M.; Witkowski, W.; Binek, M. Antimicrobial resistance in Rhodococcus equi. Acta Biochim. Pol. 2014, 61, 633-638
29. Steer, A.C.; Carapetis, J.R. Acute hematogenous osteomyelitis in children: Recognition and management. Paediatr. Drugs 2004, 6, 333-346
30. Mevius, D.J.; Koene, M.G.J.; Wit, B.; van Pelt, W.; Bondt, N. Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands. 2012. Available online: http://www.uu.nl/SiteCollection Images (accessed on 1 January 2017)
31. Diesal, A.; Moriello, K.A. A busy clinician's review of cyclosporine. Vet. Med. 2008, 103, 266. Available online: http://veterinarymedicine.dvm360.com/busy-clinicians-review-cyclosporine (accessed on 2 January 2017)
32. Nath, S.R.; Mathew, A.P.; Mohan, A.; Anila, K.R. Rhodococcusequi granulomatous mastitis in an immuno-competent patient-A case report. J. Med. Microbiol. 2013, 62, 1253-1255
33. Orsini, J.A.; Parsons, C.S.; Stine, L.; Haddock, M.; Ramberg, C.F.; Benson, C.E.; Nunamaker, D.M. Vancomycin for the treatment of methicillin-resistant staphylococcal and enterococcal infections in 15 horses. Can. J. Vet. Res. 2005, 69, 278-286
34. Matsumoto, K.; Watanabe, E.; Kanazawa, N.; Fukamizu, T.; Shiemi, A.; Yokoyama, Y.; Ikawa, K.; Morikawa, N.; Takeda, Y. Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections. Clin. Pharmacol. 2016, 8, 15-18
35. Svetitsky, S.; Leibovici, L.; Paul, M. Comparative efficacy and safety of vancomycin versus teicoplanin: Systematic review and meta-analysis. Antimicrob. Agents Chemother. 2009, 53, 4069-4079
36. Martinez, L.M.; Sanroman, J.L.; Cruz, A.M.; Tendillo, F.; Rioja, E.; Roman, F. Evaluation of safety and pharmacokinetics of vancomycin after intraosseous regional limb perfusion and comparison of results with those obtained after intravenous regional limb perfusion in horses. Am. J. Vet. Res. 2006, 67, 1701-1707
37. Slovis, N.M.; Elam, J.; Estrada, M.; Leutenegger, C.M. Infectious agents associated with diarrhoea in neonatal foals in central Kentucky: A comprehensive molecular study. Equine. Vet. J. 2014, 46, 311-316
38. Bandelj, P.; Briski, F.; Frlic, O.; Rataj, A.V.; Rupnik, M.; Ocepek, M.; Vengust, M. Identification of risk factors influencing Clostridium difficile prevalence in middle-size dairy farms. BMC Vet. Res. 2016, 47, 41
39. Keel, K.; Brazier, J.S.; Post, K.W.;Weese, S.; Songer, G. Prevalence of PCR Ribotypes among Clostridium difficile Isolates from Pigs, Calves, and Other Species. J. Clin. Microbiol. 2007, 45, 1963-1964
40. Boss, S.M.; Gries, C.L.; Kirchner, B.K.; Smith, G.D.; Francis, P.C. Use of vancomycin hydrochloride for treatment of Clostridium difficile enteritis in Syrian hamsters. J. Am. Assoc. Lab. Anim. Sci. 1994, 44, 31-37
41. Fish, R.; Nipah, R.; Jones, C.; Finney, H.; Fan, S.L. Intraperitoneal Vancomycin Concentrations during Peritoneal Dialysis-Associated Peritonitis: Correlation with Serum Levels. Perit. Dial. Int. 2012, 32, 332-338
42. British Medical Association. Vancomycin. In British National Formulary, 68th ed.; British National Formulary Publications, Royal Pharmaceutical Society of Great Britain: London, UK, 2015; Available online: http://www.bnf.org/bnf/index.htm (accessed on 8 October 2016)
43. Arias, C.A.; Singh, K.V.; Panesso, D.; Murray, B.E. Time-Kill and Synergism Studies of Ceftobiprole against Enterococcus faecalis, Including β-Lactamase-Producing and Vancomycin-Resistant Isolates. Antimicrob. Agents Chemother. 2007, 51, 2043-2047
44. Azimian, A.; Havaei, S.A.; Fazeli, H.; Naderi, M.; Ghazvini, K.; Samiee, S.M.; Soleimani, M.; Peerayeh, S.N. Genetic Characterization of a Vancomycin-Resistant Staphylococcus aureus Isolate from the Respiratory Tract of a Patient in a University Hospital in Northeastern Iran. J. Clin. Microbiol. 2012, 50, 3581-3585
45. Climo, M.W.; Patron, R.L.; Archer, G. Combinations of Vancomycin and β-Lactams are synergistic against Staphylococci with reduced susceptibilities to Vancomycin. Antimicrob. Agents Chemother. 1999, 43, 1747-1753
46. Chen, C.Y.; Huang, Y.C. Review: New epidemiology of Staphylococcus aureus infection in Asia. Clin. Microbiol. Infect. 2014, 20, 605-623
47. Tenover, F.C., Jr.; Moellering, R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 2007, 44, 1208-1215
48. Lodise, T.P.; Miller, C.D.; Graves, J.; Evans, A.; Graffunder, E.; Helmecke, M.; Stellrecht, K. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteremia. J. Antimicrob. Chemother. 2008, 62, 1138-1141
49. Rybak, M.; Lomaestro, B., Jr.; Moellering, R.; Craig, W.; Billeter, M.; Dalovisio, J.R.; Dalovisio, J.R.; Levine, D.P. Therapeutic Monitoring of Vancomycin in Adults. Am. J. Health Syst. Pharm. 2009, 66, 82-98
50. Soriano, A.; Marco, F.; Martínez, J.A.; Pisos, E.; Almela, M.; Dimova, V.P.; Alamo, D.; Ortega, M.; Lopez, J.; Mensa, J. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 2008, 46, 193-200
51. Bogaard, A.E.V.D.; Stobberingh, E.E. Epidemiology of resistance to antibiotics links between animals and humans. Int. J. Antimicrob. Agents 2000, 14, 327-335
52. Devriese, L.A.; Ieven, M.; Goossens, H.; Vandamme, P.; Pot, B.; Hommez, J.; Haesebrouck, F. Presence of vancomycin-resistant enterococci in farm and pet animals. Antimicrob. Agents Chemother. 1996, 40, 2285-2287
53. Nilsson, O. Vancomycin resistant enterococci in farm animals-Occurrence and importance. Infect. Ecol. Epidermiol. 2012, 2
54. Bogaard, A.E.V.D.; Bruinsma, N.; Stobberingh, E.E. The effect of banning avoparcin on VRE carriage in The Netherlands. J. Antimicrob. Chemother. 2000, 46, 146-148
55. Guillemot, D. Antibiotic use in humans and bacterial resistance. Curr. Opin. Microbiol. 1999, 2, 494-498
56. Lathers, C.M. Role of veterinary medicine in public health: Antibiotic use in food animals and humans and the effect on evolution of antibacterial resistance. J. Clin. Pharmacol. 2001, 41, 595-599
57. Hidayat, L.K.; Hsu, D.I.; Quist, R.; Shriner, K.A.; Beringer, W. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch. Intern. Med. 2006, 166, 2138-2144
58. Jones, R.N. Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep, Bactericidal/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant Strains. Clin. Infect. Dis. 2006, 42 (Suppl. 1), S13-S24
59. Giuliano, C.; Haase, K.K.; Hall, R. Use of vancomycin pharmacokinetic-Pharmacodynamic properties in the treatment of MRSA infections. Expert Rev. Anti-Infect. Ther. 2010, 8, 95-106
60. Brummett, R.E.; Fox, K.E. Vancomycin-and erythromycin-induced hearing loss in humans. Antimicrob. Agents Chemother. 1989, 33, 791-796
61. Elting, L.S.; Rubenstein, E.B.; Kurtin, D.; Rolston, K.V.; Fangtang, J.; Martin, C.G.; Raad, I.I.; Whimbey, E.E.; Manzullo, E.; Bodey, G.P. Mississippi mud in the 1990s: Risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 1998, 83, 2597-2607
62. Stanley, D.; McGrath, B.J.; Lamp, K.C.; Rybak, M.J. Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus. Pharmacotherapy 1994, 14, 35-39
63. Tange, R.A.; Kieviet, H.L.; Marle, J.V.; Sjoback, D.B.; Ring, W. An experimental study of vancomycin-induced cochlear damage. Arch. Otorhinolaryngol. 1989, 246, 67-70
64. Pai, M.P.; Mercier, R.C.; Koster, S.A. Epidemiology of vancomycin-induced neutropenia in patients receiving home intravenous infusion therapy. Ann. Pharmacother. 2006, 40, 224-228
65. Bishop, T. Vancomycin. In The Veterinary Formulary, 6th ed.; Pharmaceutical Press: London, UK, 2005
66. Ray, A.S.; Haikal, A.; Hammoud, K.A.; Yu, S.L. Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis. CJASN 2016, 11, 2132-2140
67. Bailie, G.R.; Neal, D. Vancomycin ototoxicity and nephrotoxicity. Med. Toxicol. Advers. Drug Exp. 1988, 3, 376-386
68. Drygalski, A.V.; Curtis, B.R.; Bougie, D.W.; McFarland, J.G.; Ahl, S.; Limbu, I.; Baker, K.R.; Aster, R.H. Vancomycin-induced immune thrombocytopenia. N. Engl. J. Med. 2007, 356, 904-910
69. Healy, D.P.; Sahai, J.V.; Fuller, S.H.; Polk, R.E. Vancomycin-induced histamine release and "red man syndrome": Comparison of 1-and 2-hour infusions. Antimicrob. Agents Chemother. 1990, 34, 550-554
70. Michael, J.R. The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin. Clin. Infect. Dis. 2006, 42, S35-S39
71. Glycopetides. Available online: http://www.merckmanuals.com/vet/search.html (accessed on 3 November 2016)
72. Radostits, O.M.; Gay, C.C.; Blood, D.C.; Hinchcliff, K.W. Veterinary Medicine: A Textbook of the Diseases of Cattle, Horses, Sheep, Pigs and Goats, 9th ed.;W B Saunders: Philadelphia, PA, USA, 2000
73. Ruben, D. Cisplatin for Dogs. 2015. Available online: http://www.petplace.com/article/drug-library/ library (accessed on 1 January 2017)
74. Cynamon, M.H.; Klemens, S.P.; Sharpe, C.A.; Chase, S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 1999, 43, 1189-1191
75. Slatter, J.G.; Adams, L.A.; Bush, C.E.; Chiba, K.; Yates, P.T.D.; Feenstra, K.L.; Koike, S.; Ozawa, N.; Peng, G.W.; Sams, J.P.; et al. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 2002, 32, 907-924
76. Vergidis, P.; Rouse, M.S.; Euba, G.; Karau, M.J.; Schmidt, S.M.; Mandrekar, J.N.; Steckelberg, J.M.; Patel, R. Treatment with Linezolid or Vancomycin in Combination with Rifampin Is Effective in an Animal Model of Methicillin-Resistant Staphylococcus aureus Foreign Body Osteomyelitis. Antimicrob. Agents Chemother. 2011, 55, 1182-1186
77. Rodriguez, A.B.; Pedrera, M.I.; Barriga, C. In vivo effect of teicoplanin and vancomycin upon haemolytic and bactericidal activity of serum against Staphylococcus aureus. Comp. Immunol. Microbiol. Infect. Dis. 1996, 19, 283-288
78. Sakai, Y.; Tsukahara, T.; Bukawa, W.; Matsubara, N.; Ushida, K. Cell Preparation of Enterococcus faecalis Strain EC-12 Prevents Vancomycin-Resistant Enterococci Colonization in the Cecum of Newly Hatched Chicks. Poultry. Sci. J. 2006, 85, 273-277